Showing 541 - 560 results of 115,706 for search '(( a non decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.81s Refine Results
  1. 541

    The MMP was decreased by incubation with CytoD or LatB. by Dong-Hee Yang (566631)

    Published 2014
    “…An MMP collapse was detected as a decrease in the percentage of cells with high red fluorescence intensity. …”
  2. 542
  3. 543
  4. 544
  5. 545
  6. 546

    The MMP was decreased by incubation with CytoD or LatB. by Dong-Hee Yang (566631)

    Published 2014
    “…An MMP collapse was detected as a decrease in the percentage of cells with high red fluorescence intensity. …”
  7. 547
  8. 548

    Functional characterization of the V9D and R10C substitutions in chicken ARF. by Doreen Schwochow Thalmann (3912649)

    Published 2017
    “…Spectra of all peptides in free form and at 25 μM concentration in complex with MDM2<sub>204-298</sub> are shown in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1006665#pgen.1006665.s008" target="_blank">S5 Fig</a>. …”
  9. 549
  10. 550
  11. 551
  12. 552
  13. 553
  14. 554

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  15. 555

    Nur77 knockdown decreases cell viability and proliferation. by Alexa Tenga (2161780)

    Published 2016
    “…<p>(A) Daoy cells were transfected with 20 nM siNur77 or non-targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every day for 3 days. …”
  16. 556
  17. 557

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  18. 558

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  19. 559
  20. 560